← Back to patent-cliff list
Atorvastatin Calcium Hydrate/Irbesartan
Tier C — Watch / tradeAtorvastatin Calcium Hydrate/Irbesartan
Hanmi Pharmaceutical Co., Ltd.
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AT1, HMGCR
Brand：Robelito
Indications (approved)：Hypertension, Hyperlipidaemia
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates10 routes
Originator routes × 2Optimised (non-patent) × 8Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OriginatorRoute 1Steps 11 · Total yield /
ATOR-001712-52-7ATOR-0025754-35-8ATOR-003110862-42-5ATOR-00479-30-1ATOR-005110862-44-7ATOR-0067342-2-1ATOR-007110862-45-8ATOR-008110862-46-9ATOR-0091429437-86-4ATOR-010134523-00-5ATOR-011125995-03-1ATOR-0123886-69-9ATOR-013—ATOR-014125995-03-1ATOR-015134523-01-6API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| ATOR-001 | 712-52-7 | ethyl 2-bromo-2-(4-fluorophenyl)acetate |
| ATOR-002 | 5754-35-8 | 2-(1,3-dioxolan-2-yl)ethanamine |
| ATOR-003 | 110862-42-5 | ethyl 2-((2-(1,3-dioxolan-2-yl)ethyl)amino)-2-(4-fluorophenyl)acetate |
| ATOR-004 | 79-30-1Available | isobutyryl chloride |
| ATOR-005 | 110862-44-7 | 2-(N-(2-(1,3-dioxolan-2-yl)ethyl)isobutyramido)-2-(4-fluorophenyl)acetic acid |
| ATOR-006 | 7342-2-1 | N,3-diphenylpropiolamide |
| ATOR-007 | 110862-45-8 | 1-(2-(1,3-dioxolan-2-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-008 | 110862-46-9 | 5-(4-fluorophenyl)-2-isopropyl-1-(3-oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-009 | 1429437-86-4 | methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-5-hydroxy-3-oxoheptanoate |
| ATOR-010 | 134523-00-5 | (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid |
| ATOR-011 | 125995-03-1 | 5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-012 | 3886-69-9Available | (R)-1-phenylethan-1-amine |
| ATOR-013 | - | 1-((3R,5R)-3,5-dihydroxy-7-oxo-7-(((R)-1-phenylethyl)amino)heptyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-014 | 125995-03-1 | 5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
OriginatorRoute 1Steps 6 · Total yield 1.42 g
IRBE-0011664-35-3IRBE-002999-09-7IRBE-003138402-05-8IRBE-004114772-54-2IRBE-005138401-24-8IRBE-00657598-33-1IRBE-0074294-57-9IRBE-00884392-32-5IRBE-009114772-53-1API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| IRBE-001 | 1664-35-3 | ethyl 1-aminocyclopentane-1-carboxylate |
| IRBE-002 | 999-09-7 | ethyl pentanimidate |
| IRBE-003 | 138402-05-8Available | 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one |
| IRBE-004 | 114772-54-2 | 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-005 | 138401-24-8 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-006 | 57598-33-1 | 2-(2-methoxyphenyl)-4,4-dimethyl-4,5-dihydrooxazole |
| IRBE-007 | 4294-57-9 | p-tolylmagnesium bromide |
| IRBE-008 | 84392-32-5 | 4,4-dimethyl-2-(4'-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole |
| IRBE-009 | 114772-53-1 | 4'-methyl-[1,1'-biphenyl]-2-carbonitrile |
OptimisedRoute 2Steps 8 · Total yield /
ATOR-015134523-01-6ATOR-016—ATOR-017519-87-9ATOR-018156051-77-3ATOR-019156051-78-4ATOR-02077-76-9ATOR-021156051-79-5ATOR-022156051-80-8ATOR-023125971-96-2ATOR-024156051-81-9ATOR-025156051-82-0API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-016 | - | (R)-ethyl 6-cyano-5-hydroxy-3-oxohexanoate |
| ATOR-017 | 519-87-9 | N,N-diphenylacetamide |
| ATOR-018 | 156051-77-3 | (R)-6-cyano-5-hydroxy-3-oxo-N,N-diphenylhexanamide |
| ATOR-019 | 156051-78-4 | (3R,5R)-6-cyano-3,5-dihydroxy-N,N-diphenylhexanamide |
| ATOR-020 | 77-76-9Available | 2,2-dimethoxypropane |
| ATOR-021 | 156051-79-5 | 2-((4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxan-4-yl)-N,N-diphenylacetamide |
| ATOR-022 | 156051-80-8 | 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)-N,N-diphenylacetamide |
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-024 | 156051-81-9 | 1-(2-((4R,6R)-6-(2-(diphenylamino)-2-oxoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
| ATOR-025 | 156051-82-0 | 1-((3R,5R)-7-(diphenylamino)-3,5-dihydroxy-7-oxoheptyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide |
OptimisedRoute 3Steps 8 · Total yield /
ATOR-015134523-01-6ATOR-02077-76-9ATOR-023125971-96-2ATOR-026105876-28-6ATOR-02780297-45-6ATOR-028125971-92-8ATOR-029125971-93-9ATOR-030125971-94-0ATOR-031125995-13-3ATOR-032125971-95-1ATOR-033134395-00-9API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-020 | 77-76-9Available | 2,2-dimethoxypropane |
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-026 | 105876-28-6 | (R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoic acid |
| ATOR-027 | 80297-45-6 | monomagnesium mono(3-(tert-butoxy)-3-oxopropanoate) |
| ATOR-028 | 125971-92-8 | (R)-tert-butyl 5-((tert-butyldimethylsilyl)oxy)-6-cyano-3-oxohexanoate |
| ATOR-029 | 125971-93-9 | (3R,5R)-tert-butyl 6-cyano-3,5-dihydroxyhexanoate |
| ATOR-030 | 125971-94-0 | tert-butyl 2-((4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-031 | 125995-13-3 | tert-butyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-032 | 125971-95-1 | tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-033 | 134395-00-9 | (3R,5R)-tert-butyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
OptimisedRoute 4Steps 14 · Total yield /
ATOR-015134523-01-6ATOR-023125971-96-2ATOR-03432328-03-3ATOR-03581927-55-1ATOR-036838906-52-8ATOR-0371404189-41-8ATOR-038838906-36-8ATOR-039—ATOR-040112904-69-5ATOR-041105-34-0ATOR-0421443774-74-0ATOR-0431443774-76-2ATOR-0441417187-90-6ATOR-045676260-68-7ATOR-046714963-28-7ATOR-047676260-66-5ATOR-0481353049-81-6ATOR-049345891-62-5API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| ATOR-015 | 134523-01-6 | sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-034 | 32328-03-3 | diethyl 3-hydroxypentanedioate |
| ATOR-035 | 81927-55-1 | benzyl 2,2,2-trichloroacetimidate |
| ATOR-036 | 838906-52-8 | diethyl 3-(benzyloxy)pentanedioate |
| ATOR-037 | 1404189-41-8 | 3-(benzyloxy)pentanedioic acid |
| ATOR-038 | 838906-36-8 | 4-(benzyloxy)dihydro-2H-pyran-2,6(3H)-dione |
| ATOR-039 | - | - |
| ATOR-040 | 112904-69-5 | (R)-3-(benzyloxy)-5-methoxy-5-oxopentanoic acid |
| ATOR-041 | 105-34-0Available | methyl 2-cyanoacetate |
| ATOR-042 | 1443774-74-0 | (5R)-dimethyl 5-(benzyloxy)-2-cyano-3-oxoheptanedioate |
| ATOR-043 | 1443774-76-2 | (R)-methyl 3-(benzyloxy)-6-cyano-5-oxohexanoate |
| ATOR-044 | 1417187-90-6 | (R)-methyl 6-cyano-3-hydroxy-5-oxohexanoate |
| ATOR-045 | 676260-68-7 | (3R,5R)-methyl 6-cyano-3,5-dihydroxyhexanoate |
| ATOR-046 | 714963-28-7 | methyl 2-((4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-047 | 676260-66-5 | methyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-048 | 1353049-81-6 | methyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-049 | 345891-62-5 | (3R,5R)-methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
OptimisedRoute 5Steps 9 · Total yield 54.80 mg
ATOR-023125971-96-2ATOR-031125995-13-3ATOR-032125971-95-1ATOR-033134395-00-9ATOR-05019790-60-4ATOR-0511182707-33-0ATOR-052129648-07-3ATOR-0531320208-68-1ATOR-0541331869-16-9ATOR-0551347738-07-1ATOR-05653503-61-0ATOR-0571331869-20-5ATOR-0581331869-21-6ATOR-0591331869-22-7API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| ATOR-023 | 125971-96-2 | 2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide |
| ATOR-031 | 125995-13-3 | tert-butyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-032 | 125971-95-1 | tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-033 | 134395-00-9 | (3R,5R)-tert-butyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| ATOR-050 | 19790-60-4 | 3-(benzyloxy)propanal |
| ATOR-051 | 1182707-33-0 | - |
| ATOR-052 | 129648-07-3 | 1,2-bis((2R,5R)-2,5-dimethylphospholan-1-yl)ethane |
| ATOR-053 | 1320208-68-1 | lithium 2,2,5,7,8-pentamethylchroman-6-olate |
| ATOR-054 | 1331869-16-9 | - |
| ATOR-055 | 1347738-07-1 | - |
| ATOR-056 | 53503-61-0 | lithium 1-(tert-butoxy)ethenolate |
| ATOR-057 | 1331869-20-5 | (R)-tert-butyl 7-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-3-oxoheptanoate |
| ATOR-058 | 1331869-21-6 | tert-butyl 2-((4R,6R)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| ATOR-059 | 1331869-22-7 | tert-butyl 2-((4R,6R)-2,2-dimethyl-6-(2-(tosyloxy)ethyl)-1,3-dioxan-4-yl)acetate |
OptimisedRoute 2Steps 5 · Total yield 380.00 mg
IRBE-010106-37-6IRBE-0111122-91-4IRBE-012873-75-6IRBE-013589-15-1IRBE-014151257-01-1IRBE-015731851-41-5IRBE-016144873-97-2API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| IRBE-010 | 106-37-6Available | 1,4-dibromobenzene |
| IRBE-011 | 1122-91-4 | 4-bromobenzaldehyde |
| IRBE-012 | 873-75-6 | (4-bromophenyl)methanol |
| IRBE-013 | 589-15-1 | 1-bromo-4-(bromomethyl)benzene |
| IRBE-014 | 151257-01-1 | 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride |
| IRBE-015 | 731851-41-5 | 3-(4-bromobenzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one |
| IRBE-016 | 144873-97-2 | (2-(1-trityl-1H-tetrazol-5-yl)phenyl)boronic acid |
OptimisedRoute 3Steps 3 · Total yield 1.83 g
IRBE-01715026-80-9IRBE-01859528-27-7IRBE-019908117-90-8IRBE-020908227-87-2IRBE-021155884-01-8API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| IRBE-017 | 15026-80-9 | 1-pentanamidocyclopentane-1-carboxylic acid |
| IRBE-018 | 59528-27-7 | (4-iodophenyl)methanamine hydrochloride |
| IRBE-019 | 908117-90-8 | N-(4-iodobenzyl)-1-pentanamidocyclopentane-1-carboxamide |
| IRBE-020 | 908227-87-2 | 2-butyl-3-(4-iodobenzyl)-1,3-diazaspiro[4.4]non-1-en-4-one |
| IRBE-021 | 155884-01-8 | (2-(1H-tetrazol-5-yl)phenyl)boronic acid |
OptimisedRoute 4Steps 4 · Total yield 1.05 g
IRBE-004114772-54-2IRBE-005138401-24-8IRBE-02217193-28-1IRBE-023638-29-9IRBE-024177219-40-8IRBE-025141745-71-3API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| IRBE-004 | 114772-54-2 | 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-005 | 138401-24-8 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-022 | 17193-28-1 | 1-aminocyclopentane-1-carboxamide |
| IRBE-023 | 638-29-9 | pentanoyl chloride |
| IRBE-024 | 177219-40-8 | 1-pentanamidocyclopentane-1-carboxamide |
| IRBE-025 | 141745-71-3 | N-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-1-pentanamidocyclopentane-1-carboxamide |
OptimisedRoute 5Steps 5 · Total yield /
IRBE-005138401-24-8IRBE-01715026-80-9IRBE-023638-29-9IRBE-026120-92-3IRBE-02749830-37-7IRBE-02892398-48-6IRBE-029133690-92-3API · Atorvastatin Calcium Hydrate/Irbesartan
| Code | CAS No. | Intermediate |
|---|---|---|
| IRBE-005 | 138401-24-8 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile |
| IRBE-017 | 15026-80-9 | 1-pentanamidocyclopentane-1-carboxylic acid |
| IRBE-023 | 638-29-9 | pentanoyl chloride |
| IRBE-026 | 120-92-3 | cyclopentanone |
| IRBE-027 | 49830-37-7 | 1-aminocyclopentane-1-carbonitrile |
| IRBE-028 | 92398-48-6 | 1-aminocyclopentane-1-carboxylic acid hydrochloride |
| IRBE-029 | 133690-92-3 | 4'-(aminomethyl)-[1,1'-biphenyl]-2-carbonitrile |
Frequently asked questions
What are the approved indications of Atorvastatin Calcium Hydrate/Irbesartan?
Approved indications include: Hypertension, Hyperlipidaemia.
When does the Atorvastatin Calcium Hydrate/Irbesartan patent expire?
No public expiry year is available for Atorvastatin Calcium Hydrate/Irbesartan yet; this page updates once verified.
How many synthesis routes are recorded for Atorvastatin Calcium Hydrate/Irbesartan?
10 synthesis routes are recorded; the shortest is 3 steps with 1.83 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Atorvastatin Calcium Hydrate/Irbesartan intermediates?
6 intermediate CAS of Atorvastatin Calcium Hydrate/Irbesartan are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Atorvastatin Calcium Hydrate/Irbesartan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29